Barinthus Biotherapeutics plc. (NASDAQ:BRNS)
| Market Cap | 30.23M-51.0% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -41.74M+39.9% |
| EPS | -1.03+40.5% |
| Shares Out | 40.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 376,145 |
| Open | 0.70 |
| Previous Close | 0.76 |
| Day's Range | 0.66 - 0.76 |
| 52-Week Range | 0.51 - 1.83 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 3.00(+305.35%) |
| Earnings Date | Nov 6, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About BRNS
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
$BRNS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BRNS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BRNS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BRNS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BRNS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BRNS from public contracts
Source: USAspending.gov
BRNS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BRNS’s recent data — informational, not investment advice